Previous close | 78.51 |
Open | 78.77 |
Bid | 79.07 x 900 |
Ask | 81.41 x 900 |
Day's range | 78.69 - 79.51 |
52-week range | 59.78 - 87.88 |
Volume | |
Avg. volume | 1,329,275 |
Market cap | 19.485B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 26.08 |
EPS (TTM) | 3.03 |
Earnings date | 25 July 2023 - 31 July 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 92.12 |
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Hologic, Masimo and Integer have been highlighted in this Industry Outlook article.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.
The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.
MARLBOROUGH, Mass., May 19, 2023--Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.